Scoping paper on the potential risk(s) of Garcinia cambogia oral consumption

Questions to the Committee

TOX/2025/41

Last updated: 27 October 2025

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

198.               The Committee are asked to consider the following questions:

a)    Does the Committee agree with the conclusions reached by ANSES?

b)    Based on the current data, is the Committee able to identify a no-observed effect level or any other options, to derive a health-based guidance value?

i)                 If no, what additional information would the Committee require to provide a risk assessment?

c)     Does the Committee have any other comments?

October 2025

Secretariat